Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Dr. Reddy’s Laboratories Ltd. ( (IN:DRREDDY) ).
Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, making it the first company to gain marketing authorization for this product in Canada. The approval, which arrived ahead of Health Canada’s review target date, covers 2 mg and 4 mg per pen presentations and carries no fixed expiry, enabling commercialization, sale, and distribution in the Canadian market.
The authorization strengthens Dr. Reddy’s position in complex generics and peptide-based therapeutics, underpinned by fully in-house API production and finished product manufacturing via partner OneSource Specialty Pharma. With launch preparations underway in what is recognized as the world’s second-largest market for Semaglutide, the company stands to benefit from rising diabetes prevalence in Canada and the growing demand for GLP-1 receptor agonist therapies among patients and healthcare systems.
More about Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, with listings in India and the U.S. The company focuses on developing and manufacturing generic and complex medicines, supported by in-house active pharmaceutical ingredient (API) and formulation capabilities, and serves regulated markets including Canada.
Average Trading Volume: 76,061
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1097.7B INR
Find detailed analytics on DRREDDY stock on TipRanks’ Stock Analysis page.